Cell News and Research

RSS

Pro-Pharmaceuticals completes $6 million private placement with 10X Fund

Pro-Pharmaceuticals, Inc., today announced that it has closed the $570,000 final tranche to complete a $6 million private placement with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants.

11 May 2010

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc., today announced the addition of Dana Farber/Harvard Cancer Center (DF/HCC) to the Phase 2 multi-center study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Platinum Resistant Ovarian Cancer." Ursula Matulonis, M.D., Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, will serve as principal investigator.

11 May 2010

DUSA Pharmaceuticals first-quarter total product revenues up 22%

DUSA Pharmaceuticals, Inc., a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010.

11 May 2010

Rosetta Genomics announces USPTO notice of allowance for Sanger hsa-miR-451

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the receipt of a new notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. patent application 11/418,870, including claims related to Sanger hsa-miR-451. miR-451 is used in the Company's miRview™ mets test, which accurately identifies the primary tumor site in patients with metastatic cancer and Cancer of Unknown Primary (CUP).

11 May 2010

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

When one of the country's foremost physicians—people like Dr. Andrew Weil—need someone to care for their friends and family dealing with cancer, the man they turn to is Keith Block, M.D. "I believe in Keith's program and would head to the Block Center if I were facing a diagnosis of cancer. It is where I have and will continue to send my friends and family," said Dr. Weil.

11 May 2010

RIKEN OSC to purchase CLC bio's high-throughput sequencing analysis solution

Today, RIKEN and CLC bio Japan announced an agreement for the purchase of CLC bio's enterprise platform software by RIKEN Omics Science Center (OSC). CLC bio's high-throughput sequence analysis infrastructure will empower both OSC's scientists and OSC's Genome Network Analysis Service (GeNAS) with a user-friendly and fast workflow to efficiently manage and analyze large quantities of genomics data.

11 May 2010

New multicenter trial achieves 71% survival in AML children

More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children's Research Hospital investigators and reported in the medical journal The Lancet Oncology. The survival rate of 71 percent is 20 percent better than previously reported U.S. rates and is similar to the success achieved in a 2009 Japanese study, said Jeffrey Rubnitz, M.D., Ph.D., a member of the St. Jude Oncology department.

11 May 2010

New combination therapy may help treat anti-estrogen resistant ER+ breast cancer

A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor positive breast cancers.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

St. Jude’s Volunteen Program offers hands-on learning experience for teenagers

They have glue on their fingers and smiles on their faces; crayons spread before them and kids crowded around them. It's all part of a day's work for the Volunteens of St. Jude Children's Research Hospital.

11 May 2010

Research may aid in developing new cancer therapies

Immortality and uncontrolled cell division are the fundamental differences between cancer cells and normal cells.

11 May 2010

Study: Omega-3 fatty acids can help mitigate bone loss

NASA-sponsored studies have found that omega-3 fatty acids found in fish oil may play a role in mitigating bone breakdown that occurs during spaceflight and in osteoporosis. Ongoing research for decades has looked for ways to stop bone density loss in astronauts.

11 May 2010

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough could lead to potential non-toxic therapies for cancer patients. The Foundation-funded investigators include Ari Melnick, M.D., of Weill Cornell Medical College, Alexander MacKerell, Ph.D., of the University of Maryland and Gilbert Priv-, Ph.D., of the University of Toronto.

11 May 2010

Folic acid supplement may improve blood flow in young amenorrheic runners

A study led by sports medicine researcher Anne Hoch, D.O. at The Medical College of Wisconsin in Milwaukee has found that oral folic acid may provide a safe and inexpensive treatment to improve vascular function in young female runners who are amenorrheic (not menstruating).

11 May 2010

New findings could help develop vaccines against respiratory infections

Inducing cellular immunity as a means to protect against influenza virus is the focus of several laboratories at the Trudeau Institute. Researchers here have recently identified two important signaling components required by the immune system that might allow us to pre-position our own virus-fighting T cells to the lungs, the site of initial infection.

11 May 2010

Dyslexic children may have structural differences in brain region, says study

Children with dyslexia often struggle with reading, writing, and spelling, despite getting an appropriate education and demonstrating intellectual ability in other areas.

11 May 2010

Patients with semantic dementia have altered sense of flavours

Flavour is literally the spice of life and for many people life without the pleasures of the table would be unthinkable. Yet just this aspect of everyday life is vulnerable in certain degenerative dementias, with patients developing abnormal eating behaviours including changes in food preferences, faddism and pathological sweet tooth.

11 May 2010

Dendreon reports $125.7 million net loss for first-quarter 2010

Dendreon Corporation today reported results for the quarter ended March 31, 2010. Revenue for the quarter ended March 31, 2010 was $21,000 compared to $30,000 for the quarter ended March 31, 2009.

11 May 2010

Aastrom Biosciences reports third quarter 2010 FY results

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also announced progress in its late-stage clinical development programs and corporate operations.

11 May 2010

ImmunoGen announces underwriter's exercise of over-allotment option

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 1,350,000 shares of common stock at a public offering price of $8.00 per share.

10 May 2010